Teprotumumab, an anti-IGF-1R monoclonal antibody, has demonstrated efficacy in severe TAO through randomized Phase II and III trials, with significant symptom relief and minimal adverse effects [345, 346]. Here, IGF1R is linked to thromboangiitis obliterans.